Sitemap
- Company
- About PAION
- Events
- Newsroom
- 2010
- Press release: PAION starts Phase IIb study with its short-acting anaesthetic/sedative CNS 7056 in patients undergoing colonoscopy
- Press release: PAION AG reports results for the first quarter 2010
- Press release: PAION AG enters into an equity facility agreement for EUR 15 million
- Ad hoc: PAION AG enters into an equity facility agreement for EUR 15 million
- Press release: Start of Japanese Phase I with CNS 7056 triggered first milestone of one million USD for PAION from Ono Pharmaceutical
- Press release: PAION reaches agreement with FDA on Phase IIb study design for its short-acting anaesthetic/sedative CNS 7056 in patients undergoing colonoscopy
- Press release: Filing of IND application for GGF2 in heart failure by PAION’s partner Acorda Therapeutics triggers first milestone payments
- Press release: PAION’s partner Lundbeck initiates Japanese Clinical Phase II Trial with Desmoteplase in ischaemic stroke
- Press release: PAION AG reports results for the fiscal year 2009
- Press release: PAION’s Partner Lundbeck Presented Data From a post-hoc Analysis Using Desmoteplase in Ischaemic Stroke
- Press release: PAION announces initiation of clinical development activities with short-acting anaesthetic/sedative CNS 7056 (ONO’s Development code: ONO-2745) by its Partner ONO Pharmaceutical in Japan
- Archive 2009
- Press release: PAION reports positive results of its short acting anaesthetic/sedative CNS 7056 in a Phase IIa study in upper GI endoscopy
- Press release: PAION AG reports results for the first nine months 2009
- Ad hoc: PAION reports positive results of its short acting anaesthetic/sedative CNS 7056 in a Phase IIa study in upper GI endoscopy
- Press release: Phase Ib study endpoint achieved with PAION's short acting anesthetic/sedative CNS 7056
- Press Release: Change in PAION AG Management Board
- Press release: PAION announces completion of Phase Ib study with its short acting anesthetic/sedative CNS 7056
- Press release: Abstract on CNS 7056 has been chosen as one of the best abstracts by the American Society Of Anesthesiologists (ASA)
- Press release: PAION Announces Patient Recruitment for Phase IIa Study with its Short Acting Anesthetic/Sedative CNS 7056 Successfully Completed
- Press release: PAION to Present at Five Upcoming Conferences
- Press release: PAION AG reports results for the first half year 2009
- Press release: Phase Ib and IIa studies of the anesthetic/sedative CNS 7056 on track
- Press release: PAION AG Reports Results for the First Quarter 2009
- Press release: PAION Completes First Part of Phase Ib Study of the anesthetic/sedative CNS 7056
- Press release: PAION Initiates Phase Ib Study of the Anesthetic/Sedative CNS 7056 in Volunteers Undergoing Colonoscopy
- Press release: PAION Initiates Phase II Trial with its Anesthetic/Sedative CNS 7056
- Press release: PAION and ERGOMED report full data of CNS 5161 Phase IIa study in neuropathic cancer pain
- Press release: PAION AG reports consolidated financial results for the fiscal year 2008
- Ad hoc: PAION AG - Notice of Cancellation of AIM Listing
- Voting rights notification Barclays
- Press release: PAION's novel sedative/anaesthetic CNS 7056 meets target profile in human proof of concept study
- Archive 2008
- Press release: PAION and ERGOMED complete enrolment of Phase IIa study with CNS 5161 in opioid-refractory cancer pain
- Press release: PAION's partner Lundbeck initiates clinical phase III trials with Desmoteplase in ischaemic stroke
- Press release: PAION announces dosing of first healthy volunteers in Phase I study with its sedative/anaesthetic CNS 7056
- Press release: PAION sees improved probability of success for pain drug M6G following successful meta-analysis of clinical data
- Holdings in company (ATM Limited, Avlar)
- Press release: PAION announces Phase I study with sedative/anaesthetic CNS 7056 progressed to midazolam comparison - Today company presentation at UBS Global Life Sciences Conference
- Press release: PAION AG reports results for the first half-year 2008 and provides strategy update
- Holdings in company (Innoven)
- Holdings in company (Gartmore)
- Press release PAION AG: New Supervisory Board Member appointed
- Holdings in company (Gartmore)
- Press release: PAION announces dosing of first healthy volunteers in Phase I study with its sedative/anaesthetic CNS 7056
- Regulatory release: Announcement according to Sec 37w WpHG: Publication date for half-year report 2008
- Press release: PAION announces plan to commence clinical program with its sedative CNS 7056
- Holdings in company (Gartmore)
- Holdings in company (Barclays)
- Holdings in company (3i)
- Holdings in company (Omega)
- Total voting rights
- Directors' Shareholdings (Dres. Söhngen)
- Press release: PAION AG completes acquisition of CeNeS
- Press release PAION AG: Court sanctions Scheme of Arrangement for acquisition of CeNeS
- Press release PAION AG: shareholders of CeNeS vote for acquisition by PAION
- Press release: PAION's anticoagulant Solulin achieves proof of concept for mode of action in Phase I
- Press release: PAION Annual General Meeting and CeNeS Acquisition Update
- Press release: PAION AG reports results for the first quarter 2008
- Press release: PAION AG acquires world-wide rights to anticoagulant flovagatran from UK company Trigen
- Press release: PAION AG intends to acquire CeNeS Pharmaceuticals plc
- Press release: PAION publishes financial results for fiscal year 2007
- Press release: PAION’s anticoagulant Solulin successfully tested in first-in-man study
- Press release: PAION agreement with Lundbeck comes into force
- Archive 2007
- Archive 2006
- Archive 2005
- Archive 2004
- Archive 2003
- Media centre
- Contact for the press
- 2010
- Contact
- Investors
- Newsroom
- 2010
- Press release: PAION starts Phase IIb study with its short-acting anaesthetic/sedative CNS 7056 in patients undergoing colonoscopy
- Press release: PAION AG reports results for the first quarter 2010
- Press release: PAION AG enters into an equity facility agreement for EUR 15 million
- Ad hoc: PAION AG enters into an equity facility agreement for EUR 15 million
- Press release: Start of Japanese Phase I with CNS 7056 triggered first milestone of one million USD for PAION from Ono Pharmaceutical
- Press release: PAION reaches agreement with FDA on Phase IIb study design for its short-acting anaesthetic/sedative CNS 7056 in patients undergoing colonoscopy
- Press release: Filing of IND application for GGF2 in heart failure by PAION’s partner Acorda Therapeutics triggers first milestone payments
- Press release: PAION’s partner Lundbeck initiates Japanese Clinical Phase II Trial with Desmoteplase in ischaemic stroke
- Press release: PAION AG reports results for the fiscal year 2009
- Press release: PAION’s Partner Lundbeck Presented Data From a post-hoc Analysis Using Desmoteplase in Ischaemic Stroke
- Press release: PAION announces initiation of clinical development activities with short-acting anaesthetic/sedative CNS 7056 (ONO’s Development code: ONO-2745) by its Partner ONO Pharmaceutical in Japan
- Archive 2009
- Press release: PAION reports positive results of its short acting anaesthetic/sedative CNS 7056 in a Phase IIa study in upper GI endoscopy
- Press release: PAION AG reports results for the first nine months 2009
- Ad hoc: PAION reports positive results of its short acting anaesthetic/sedative CNS 7056 in a Phase IIa study in upper GI endoscopy
- Press release: Phase Ib study endpoint achieved with PAION's short acting anesthetic/sedative CNS 7056
- Press Release: Change in PAION AG Management Board
- Press release: PAION announces completion of Phase Ib study with its short acting anesthetic/sedative CNS 7056
- Press release: Abstract on CNS 7056 has been chosen as one of the best abstracts by the American Society Of Anesthesiologists (ASA)
- Press release: PAION Announces Patient Recruitment for Phase IIa Study with its Short Acting Anesthetic/Sedative CNS 7056 Successfully Completed
- Press release: PAION to Present at Five Upcoming Conferences
- Press release: PAION AG reports results for the first half year 2009
- Press release: Phase Ib and IIa studies of the anesthetic/sedative CNS 7056 on track
- Press release: PAION AG Reports Results for the First Quarter 2009
- Press release: PAION Completes First Part of Phase Ib Study of the anesthetic/sedative CNS 7056
- Press release: PAION Initiates Phase Ib Study of the Anesthetic/Sedative CNS 7056 in Volunteers Undergoing Colonoscopy
- Press release: PAION Initiates Phase II Trial with its Anesthetic/Sedative CNS 7056
- Press release: PAION and ERGOMED report full data of CNS 5161 Phase IIa study in neuropathic cancer pain
- Press release: PAION AG reports consolidated financial results for the fiscal year 2008
- Ad hoc: PAION AG - Notice of Cancellation of AIM Listing
- Voting rights notification Barclays
- Press release: PAION’s novel sedative/anaesthetic CNS 7056 meets target profile in human proof of concept study
- Archive 2008
- Press release: PAION and ERGOMED complete enrolment of Phase IIa study with CNS 5161 in opioid-refractory cancer pain
- Press release: PAION's partner Lundbeck initiates clinical phase III trials with Desmoteplase in ischaemic stroke
- Press release: PAION announces successful completion of Phase I study with the sedative/anaesthetic CNS 7056
- Press release: PAION AG reports nine-months results 2008
- Holdings in company (ATM Limited, Avlar)
- Press release: PAION sees improved probability of success for pain drug M6G following successful meta-analysis of clinical data
- Press release: PAION announces Phase I study with sedative/anaesthetic CNS 7056 progressed to midazolam comparison
- Press release: PAION AG reports results for the first half-year 2008 and provides strategy update
- Holdings in company (Innoven)
- Holdings in company (Gartmore)
- Press release: New Supervisory Board Member appointed
- Holdings in company (Gartmore)
- Regulatory release: Announcement according to Sec 37w WpHG: Publication date for half-year report 2008
- Press release: PAION announces dosing of first healthy volunteers in Phase I study with its sedative/anaesthetic CNS 7056
- Press release: PAION announces plan to commence clinical program with its sedative CNS 7056
- Holdings in company (Gartmore)
- Holdings in company (Barclays)
- Holdings in company (3i)
- Holdings in company (Omega)
- Total voting rights
- Directors' Shareholdings (Dres. Söhngen)
- Ad hoc & press release: PAION AG completes acquisition of CeNeS
- Press release: Court sanctions Scheme of Arrangement for acquisition of CeNeS
- Press release: shareholders of CeNeS vote for acquisition by PAION
- PAION's anticoagulant Solulin achieves proof of concept for mode of action in Phase I
- Press release: PAION Annual General Meeting and CeNeS Acquisition Update
- Press release: PAION AG reports results for the first quarter 2008
- Press release: PAION AG acquires world-wide rights to anticoagulant flovagatran from UK company Trigen
- Ad hoc & press release: PAION AG intends to acquire CeNeS Pharmaceuticals plc
- Press release: PAION AG reports financial results for fiscal year 2007
- PAION's anticoagulant Solulin successfully tested in first-in-man study
- Ad hoc & press release: PAION agreement with Lundbeck comes into force
- Archive 2007
- Archive 2006
- Archive 2005
- Archive 2004
- Archive 2003
- 2010
- Reports
- Presentations
- Corporate Calendar
- Annual General Meeting
- Corporate Governance
- Directors' Dealings
- Information on shares
- Annual Document pursuant Sec 10 WpPG
- Contact for Investors & Analysts
- Newsroom
- Pipeline
- Career
Copyright © 2001 - 2010 PAION AG. All rights reserved. E-Mail: info@paion.com